Collegium Pharmaceuticals presents data on Jornay PM for ADHD treatment at NAPNAP conference.

From GlobeNewswire: 2025-03-10 18:57:14

Collegium Pharmaceutical, Inc. announced two poster presentations at the NAPNAP conference on ADHD treatment with Jornay PM. Real-world data will be highlighted, demonstrating the benefit of Jornay PM for the ADHD community. ADHD is a common childhood psychiatric condition with behavioral symptoms, and Jornay PM is a CNS stimulant used for treatment. Jornay PM is a federally controlled substance due to its high potential for abuse and misuse. Important safety information includes risks of heart problems, increased blood pressure, mental issues, and more. Jornay PM should not be taken if allergic to methylphenidate or MAOIs.

Read more at GlobeNewswire: Collegium Announces Poster Presentations at the 2025